Teva Announces Exclusive Launch of Generic Pataday® in the United States

Monday, Jun 12, 2017

Teva Pharmaceutical Industries Ltd., announced the launch of generic Pataday®1 (olopatadine hydrochloride ophthalmic solution) 0.2%, in the U.S.

Olopatadine hydrochloride ophthalmic solution 0.2% is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Teva is committed to strengthening its generics business through continued investment in complex, high-quality products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva product.

“Olopatadine hydrochloride ophthalmic solution 0.2% is an important treatment for our patients and a key addition to our generics product portfolio,” said Dipankar Bhattacharjee, Teva’s President and CEO, Global Generic Medicines. “This launch marks another successful first-to-file product for Teva, bringing the only generic version of this product on the market.”

Pataday® had annual sales of approximately $303 million in the U.S., according to IMS data as of March 2017.



Other News